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design including internal normal skin 
controls. Developments in other spe-
cialties are also showing us the way 
for broader use, for instance in the 
study of tumors (Dabrosin, 2005).
Writing a Commentary such as this 
can make the author feel challenged 
— “So much to do (refer to) and so 
little time (column space).” Read the 
article by Morgan et al.(2006); fol-
low the trail provided by the sub-
jects and authors referred to there 
and in this commentary. It will lead 
you to around 500 articles involving 
microdialysis and skin, around 3,000 
articles on human microdialysis in 
a wide range of organs and applica-
tions, and a total microdialysis bibli-
ography approaching 10,000 articles. 
Think broadly about the opportunities 
offered by cutaneous microdialysis for 
application in your own special area 
of research. You will very likely find it 
worth the sweat!
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The Skin as a Site of Initiation of 
Systemic Autoimmune Disease: New 
Opportunities for Treatment
Jan P. Dutz1,2
Dendritic cells are the coordinators of the adaptive immune response. Chronic 
activation of skin dendritic cells by keratinocyte expression of CD40 ligand 
(CD40L; CD154) leads to autoimmunity. In this issue, systemic administration of 
tacrolimus is shown by Loser et al. to effectively treat autoimmunity in a murine 
model involving transgenic keratinocyte expression of CD40L.
Journal of Investigative Dermatology (2006) 126, 1209–1212. doi:10.1038/sj.jid.5700238
Chronic skin dendritic-cell activation 
and autoimmunity
Over the past 20 years, dendritic cells 
have become recognized as the prime 
orchestrators of the adaptive immune 
response (Banchereau and Steinman, 
1998). These cells most efficiently acti-
vate or prime T cells (Inaba et al., 1990). 
More recently, their dual role as inhibi-
tory regulators of the immune response 
has been appreciated (Hawiger et al., 
2001). For example, Langerhans cells, 
long thought to be proinflammatory 
sentinels, have been shown to be dis-
pensable for the cutaneous (Allan et al., 
2003) or mucosal (Zhao et al., 2003) 
priming of cytotoxic T cells to herpes 
simplex virus and to have a potentially 
suppressive role in contact hypersen-
sitivity responses (Kaplan et al., 2005). 
With this dual role, dendritic cells are 
probably key players in the march to 
autoimmunity.
Proinflammatory stimulation of 
dendritic cells with activation signals 
such as Toll-like receptors (Iwasaki and 
Medzhitov, 2004) or CD40 ligation 
(Ridge et al., 1998) results in the matu-
ration of dendritic cells and subsequent 
efficient T-cell activation. Chronic den-
dritic-cell stimulation may result in an 
autoimmune phenotype. For example, 
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overexpression of CD40 ligand (CD40L; 
CD154) in the basal layer of the skin 
results in local emigration of dendritic 
cells (Langerhans cells), accumulation 
of dendritic cells in the draining lymph 
nodes with ensuing local lymphade-
nopathy, and a CD8+ T cell-mediated 
autoimmune disease. This experimental 
murine disease model is characterized 
by cellular autoimmune responses in 
the skin and formation of autoantibodies 
against nuclear antigens, including anti-
DNA antibodies (Mehling et al., 2001). 
Likewise, overexpression of CD154 in 
pancreatic islets leads to islet inflam-
mation (insulitis) and eventual diabetes 
(Haase et al., 2004) that are both T and 
B cell dependent.
These models show that chronic den-
dritic-cell activation can lead to local 
as well as systemic autoimmunity. In 
the model developed by Mehling et 
al. (2001), cutaneous disease could 
be transferred from transgenic to non-
transgenic animals by CD8+ T-cell trans-
fer, indicating that autoreactive CD8+ T 
cells were sufficient to mediate skin dis-
ease and the lupus-like phenotype. How 
well do these models reflect spontaneous 
human autoimmune disease? Recently, 
it has been demonstrated that propor-
tions of effector-type, perforin-express-
ing CD8+ T cells increase in active 
systemic lupus erythematosus and cor-
relate with disease activity (Blanco et 
al., 2005). Further, scarring lesions of 
discoid lupus erythematosus are charac-
terized by high numbers of skin-homing 
cytotoxic CD8+ T lymphocytes (Wenzel 
et al., 2005). These observations endorse 
a potential pathogenic role for CD8+ T 
cells in lupus autoimmunity and suggest 
that the model of Mehling et al. may in 
part mirror human lupus autoimmunity. 
Interestingly, increased skin CD40L 
expression (Ohta and Hamada, 2004), 
decreased numbers of potentially 
tolerogenic epidermal Langerhans cells 
(Gordon et al., 2005), and increased 
numbers of inflammatory dermal and 
epidermal dendritic cells (Lowes et al., 
2005) have been noted in lesional pso-
riasis, another disorder in which acti-
vated CD8+ T cells (Austin et al., 1998) 
have been implicated. This suggests 
that the model of Mehling et al. may 
also mirror other forms of skin autoim-
munity. Collectively, the data suggest 
that dendritic cells are at the nexus of 
autoimmunity initiation and inhibition 
and that pharmacological control of the 
dendritic cells may have significant and 
yet unexplored benefits in the therapy 
and prevention of autoimmunity.
Calcineurin inhibitors and systemic 
autoimmunity
Calcineurin inhibitors have been in 
clinical use in dermatology for over 
20 years. Cyclosporine is a cyclic 
polypeptide that has been used in renal 
organ transplantation and for multiple 
dermatoses with excellent clinical 
responses in psoriasis, pyoderma gan-
grenosum, Behçet’s disease, and lichen 
planus (Ho et al., 1990). The mechanism 
of action of cyclosporine is now known 
to be related to the reduction of the cal-
cineurin activity of T cells, resulting in 
decreased cytokine gene transcription 
(reviewed by Cardenas et al., 1995), 
and decreased cytotoxic degranula-
tion (Ambach et al., 2001; Dutz et al., 
1993). Tacrolimus (FK506) is a macro-
lide antibiotic that has a mechanism of 
action similar to that of cyclosporine, 
albeit with 10–100 times greater mole-
cular potency and a smaller molecular 
weight. This has resulted in an effec-
tive topical formulation (Evans, 2005). 
Tacrolimus has been used as an alterna-
tive calcineurin inhibitor for organ trans-
plantation since the 1990s (Taylor et al., 
2005). Side effects of cyclosporine and 
tacrolimus include renal nephrotoxicity 
and neurotoxicity (reviewed by Taylor et 
al., 2005). Systemic cyclosporine use in 
transplantation is associated with more 
nephrotoxicity, whereas tacrolimus use 
is associated with more neurotoxicity 
and drug-induced diabetes (Webster et 
al., 2005).
A limited number of studies have 
examined the use of oral tacrolimus for 
the treatment of systemic autoimmune 
disease. Tacrolimus has been used 
investigationally in rheumatoid arthritis 
(Furst et al., 2002), polymyositis with 
interstitial lung disease (Oddis et al., 
1999), scleroderma (Morton and Powell, 
2000), and systemic lupus erythemato-
sus (Duddridge and Powell, 1997; Politt 
et al., 2004) with variable effect. In this 
issue, Loser et al. (2006) demonstrate 
that systemic tacrolimus controls murine 
keratinocyte-expressed CD40L-induced 
skin and systemic autoimmunity. They 
convincingly demonstrate that this drug 
is able to reverse and prevent autoreac-
tive CD8+ T-cell activation. Thus, CD8+ 
T cells from untreated but not from 
treated animals were able to transfer 
skin disease. Tacrolimus treatment also 
led to decreased lymphadenopathy and 
decreased autoantibody formation and 
glomerular deposition.
Recent evidence suggests that cal-
cineurin inhibitors inhibit the antigen-
presenting function of dendritic cells 
(Lee et al., 2005) independently of 
T-cell effects. Unfortunately, the rela-
tive importance of this mode of action 
of the calcineurin inhibitors was not 
commented upon by Loser et al. (2006). 
Further, it remains unclear whether the 
salutary effect on autoantibody pro-
duction was due to a direct action of B 
cells or to indirect effects on cytotoxic 
T cells, CD4+ T cells, or dendritic cells. 
Despite these minor shortcomings, the 
authors have ably used a novel and 
relevant model of skin-initiated auto-
immunity to study the pharmaco-
biology of a currently available and 
effective immunomodulator.
Lessons for clinical practice
What lessons can we glean? To the 
clinician-scientist, this work points out 
the importance of refining our under-
standing of current immunotherapies for 
autoimmune disease. The remarkable 
success noted in this murine model con-
trasts with the variable results noted in 
clinical systemic autoimmune disease 
(Mayer and Kushwaha, 2003). This may 
be a result of the higher doses used in 
this animal model (up to ~4 mg per kg 
per day on average) as compared with 
the doses commonly used in human 
clinical trials for the treatment of auto-
immune disease (0.06–0.1 mg per 
kg per day) or in transplantation (0.2–
0.3 mg per kg per day). Interestingly, 
after kidney transplantation, calcineurin 
|Dendritic cells are probably key players in the march to 
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inhibitors have been shown to prevent 
recurrence of systemic lupus erythe-
matosus (Dong et al., 2005). Should 
the skin dendritic cell be found to be 
a major in vivo locus of action for sys-
temic calcineurin inhibitors, this would 
point to the importance of targeting the 
skin-resident dendritic cells directly 
with potentially less toxic topical ther-
apy. The active form of vitamin D, 1α-
dihydroxyvitamin D3, for example, is 
known to alter or inhibit maturation of 
dendritic cells and promote a tolerogen-
ic phenotype (Berer et al., 2000). Patients 
with systemic lupus erythematosus are 
advised to avoid sunlight and often 
have vitamin D deficiency (Huisman 
et al., 2001). Yet the use of topical vita-
min D analogues such as calcipotriol 
as adjuncts in the management of skin 
lupus remains largely unexplored. The 
efficacy of systemic calcineurin inhibi-
tors in controlling pathogenic CD8+ 
T-cell activation as described here 
should also remind us of the possible 
short-term systemic use of these agents 
in severe dermatologic conditions in 
which CD8+ T-cell cytotoxic assault 
has been implicated. Such conditions 
include systemic drug hypersensitiv-
ity reactions (Zuliani et al., 2005), toxic 
epidermal necrolysis (Chave et al., 
2005), and possibly “hyperacute” toxic 
epidermal necrolysis-like cutaneous 
lupus erythematosus (Ting et al., 2004).
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"Bak (and Bax) to the Future" — of 
Primary Melanoma Prognosis?
Martin Leverkus1 and Harald Gollnick1
Bcl-2 proteins either block or activate the “intrinsic” mitochondrial apoptosis path-
way. Loss of expression of proapoptotic Bcl-2 proteins, namely Bax and Bak, in pri-
mary melanomas is associated with a worse long-term prognosis. Consequently, 
inactivation of mitochondrial signaling pathways of apoptosis may not only be a 
prerequisite for melanoma progression but may also hamper therapeutic efforts 
with chemotherapeutic drugs. 
Journal of Investigative Dermatology (2006) 126, 1212–1214. doi:10.1038/sj.jid.5700239
Despite major efforts to improve diag-
nosis and stage-specific therapy, the 
incidence of melanoma and its mortality 
rates have increased continuously over 
the past two decades. Unfortunately, 
the prognosis of melanoma patients 
with progressive disease is poor, in par-
ticular for patients with thick lesions or 
regional lymph node metastasis. For 
these patients, there is no general agree-
ment among dermato-oncologists about 
evidence-based treatment modalities 
(Queirolo et al., 2005). Extensive studies 
during the past years have clarified that 
alterations within physiological signaling 
cascades of melanoma cells may be of 
utmost importance for the understanding 
of drug resistance mechanisms and con-
sequently for clinical outcome following 
treatment (Soengas and Lowe, 2003). 
One major challenge is the definition of 
wider arrays of prognostic parameters for 
melanoma after surgical excision of the 
primary tumor, which may subsequently 
justify prognosis-adapted treatment regi-
mens for the patient. This strategy in turn 
may rely on information gained from 
the primary melanoma about signal-
ing pathways activated or silenced dur-
ing melanomagenesis (for review see 
Chudnovsky et al., 2005). One decisive 
factor for successful tumor therapy is 
the initiation of the cell-intrinsic apop-
totic program that is largely dependent 
on activation of the central executioners 
of apoptosis, the caspases (Lavrik et al., 
2005). Their activity is critical not only 
for successful tumor-cell death but also 
for the mounting of a tumor-specific 
immune response (Casares et al., 2005). 
Thus the understanding of apoptosis 
signaling in melanoma may ultimately 
result in better treatment strategies for 
this deadly tumor.
Apoptosis is tightly regulated in a 
cell-specific manner by multiple signal-
ing pathways that interact in successive 
and interconnected amplification loops, 
finally resulting in cell demise. In this 
issue, Fecker et al. (2006) have tackled 
the task of identifying novel prognos-
tic markers in primary melanomas by 
expression analysis of several pro- and 
antiapoptotic proteins in vivo. The authors 
first carefully explored the specificity of 
their immunohistochemical analysis by 
demonstrating positive as well as nega-
tive staining of different tumor samples. 
Upon subdivision of the samples accord-
ing to the presence or absence of clini-
cal progression of these tumors over a 
 follow-up period of 10 years, these 
tumors were investigated for the prognos-
tic relevance of protein expression. What 
type of signals may lead to apoptosis in 
melanoma? In general, apoptotic signal-
ing is broadly divided into “intrinsic” and 
“extrinsic” pathways: the extrinsic path-
way is triggered from the outside of the 
cell by transmembrane proteins called 
death receptors (Locksley et al., 2001). 
These trigger apoptosis by ligand binding 
via recruitment of the initiator caspases 
caspase-8 and/or caspase-10, ultimately 
resulting in activation of effector cas-
pases (for example, caspase-3; Figure 1). 
However, this pathway is tightly regu-
lated by intracellular initiator caspase 
inhibitors such as cFLIP, and this inhibi-
tion seems to be operative in melanoma 
(Bullani et al., 2001). Fecker et al. (2006) 
investigated the protein expression of 
the death receptors DR4 (tumor necrosis 
factor-related apoptosis-inducing ligand-
receptor 1 (TRAIL-R1)) and DR5 (TRAIL-
R2) and important cell cycle regulators 
such as p21 and retinoblastoma pro-
tein, the tumor suppressor p53, and its 
inhibitor MDM2. These studies, although 
performed only in a limited number of 
superficial spreading melanomas (SSMs), 
did not show a significant correlation 
to the prognosis of primary melanoma. 
TRAIL-R1 and TRAIL-R2 were expressed 
in over 90% of primary SSMs, demon-
strating that these two death receptors do 
not predict clinical outcome. However, 
because the death ligand TRAIL or ago-
nistic antibodies to TRAIL-R1 or TRAIL-
R2 are currently undergoing extensive 
preclinical tests for tumor therapy (Kelley 
and Ashkenazi, 2004), these results of 
Fecker et al. (2006), if confirmed in larger 
series of tumors as well as melanoma 
metastasis in vivo, might open a thera-
peutic window for these agents for 
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